Form 8-K - Current report:
SEC Accession No. 0001628280-21-022729
Filing Date
2021-11-10
Accepted
2021-11-10 12:54:37
Documents
15
Period of Report
2021-11-09
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crdf-20211109.htm   iXBRL 8-K 38123
2 EX-99.1 a991ex110921.htm EX-99.1 13256
6 cardiff_logoxrgbxtm.jpg GRAPHIC 176318
7 crdf-20211109_g1.jpg GRAPHIC 176318
  Complete submission text file 0001628280-21-022729.txt   852501

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT crdf-20211109.xsd EX-101.SCH 1935
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT crdf-20211109_lab.xml EX-101.LAB 23007
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT crdf-20211109_pre.xml EX-101.PRE 12131
8 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20211109_htm.xml XML 10069
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35558 | Film No.: 211395654
SIC: 2836 Biological Products, (No Diagnostic Substances)